Phathom Pharmaceuticals (PHAT) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PHAT Stock Alerts $9.67 +0.14 (+1.47%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 4:03 PM | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call TranscriptMay 10 at 9:35 AM | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday.May 10 at 8:00 AM | investorplace.comThe 3 Best Healthcare Stocks to Buy in May 2024May 9, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday.May 9, 2024 | globenewswire.comPhathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Promising Pipeline DevelopmentsMay 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial OutlookMay 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.9%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 5.9%May 7, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Recommendation for Stoke Therapeutics Amidst Strategic Progress and Anticipated Clinical MilestonesMay 7, 2024 | americanbankingnews.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCMay 6, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 11.8%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 11.8%May 5, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up to $9.76May 5, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Coverage Initiated at Stifel NicolausMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market TrajectoryMay 3, 2024 | msn.comStifel Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy RecommendationMay 3, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday.May 3, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus began coverage on Phathom Pharmaceuticals in a research note on Friday. They set a "buy" rating and a $24.00 target price for the company.May 2, 2024 | msn.comPeloton stock sinks to record low as CEO steps downMay 2, 2024 | msn.comMiami sports mogul receives $10 billion offer for his assets, here's why he rejected the dealApril 29, 2024 | finance.yahoo.comPhathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024April 26, 2024 | markets.businessinsider.comBuy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oqueznaApril 23, 2024 | markets.businessinsider.comNeedham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)April 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oqueznaApril 19, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.7% Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.7%April 19, 2024 | finance.yahoo.com12 Most Shorted Stocks in 2024April 15, 2024 | marketbeat.comVanguard Group Inc. Has $19.94 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Vanguard Group Inc. increased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 10.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,922,662 shares of the company's stockApril 12, 2024 | investing.comPhathom Pharmaceuticals CFO sells over $38k in company stockApril 11, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.2% After Insider SellingPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.2% After Insider SellingApril 11, 2024 | insidertrades.comMolly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockApril 10, 2024 | markets.businessinsider.comBuy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising PipelineApril 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)April 7, 2024 | msn.comPhathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analystApril 6, 2024 | markets.businessinsider.comOptimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data FluctuationsApril 5, 2024 | finance.yahoo.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist InvestorsApril 4, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 5.5%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5%April 3, 2024 | finance.yahoo.comPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | globenewswire.comPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 8.1%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 8.1%April 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)March 28, 2024 | stockhouse.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"March 28, 2024 | investing.comPhathom Pharmaceuticals CEO sells shares worth over $153,000March 27, 2024 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 16,851 SharesMarch 26, 2024 | marketbeat.comTerrie Curran Sells 16,851 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) insider Terrie Curran sold 16,851 shares of the firm's stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the completion of the transaction, the insider now directly owns 410,784 shares of the company's stock, valued at $3,742,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 26, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 5.6%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 5.6% HigherMarch 26, 2024 | finance.yahoo.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”March 25, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4.5% Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4.5%March 25, 2024 | finance.yahoo.comSIGA Names Larry Miller General CounselMarch 23, 2024 | markets.businessinsider.comPositive Prescription Trends and Resilience Prompt Buy Rating for Phathom PharmaceuticalsMarch 22, 2024 | marketbeat.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… PHAT Media Mentions By Week PHAT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.730.57▲Average Medical News Sentiment PHAT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼153▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IGM Biosciences News Calliditas Therapeutics AB (publ) News ArriVent BioPharma News Stoke Therapeutics News Aerovate Therapeutics News GH Research News Olema Pharmaceuticals News Avid Bioservices News Zymeworks News Pharming Group News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
